Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PAM | P19021 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68851 | 0.90 | CYP4Z1 (0.62) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL1810195 | 0.86 | L3MBTL1 (0.45) | CYP4Z1MAPTSMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL1687054 | 0.85 | LMNA (0.54) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL184705 | 0.85 | CYP4Z1 (0.54) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL6057577 | 0.84 | CYP4F2 (0.59) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL10299459 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL1107146 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL68930 | 0.84 | CYP4Z1 (0.57) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 | |
| SCHEMBL181473 | 0.83 | HPGD (0.61) | CYP4Z1MAPTSMN1; SMN2ALDH1A1TBXAS1 | |
| SCHEMBL6207253 | 0.82 | CYP4Z1 (0.55) | CYP4Z1MAPTLMNASMN1; SMN2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | CYP4Z1 2338/4885MAPT 1025/4885LMNA 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.